Trial Outcomes & Findings for Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma (NCT NCT01476787)
NCT ID: NCT01476787
Last Updated: 2025-05-14
Results Overview
The Complete Response Rate (CR/CRu) is the percentage of participants who achieve complete response (CR/CRu) at 120 weeks as assessed per Independent Central Review. * Complete Response (CR): Disappearance of all evidence of disease. * Complete Response Unconfirmed (CRu): Disappearance of all disease with the exception of residual lymph nodes that are 1.5 cm or less in greatest transverse diameter and/or indeterminate bone marrow findings.
Recruitment status
COMPLETED
Study phase
PHASE3
Target enrollment
1030 participants
Primary outcome timeframe
At 120 weeks
Results posted on
2025-05-14
Participant Flow
1030 participants were randomized, 1010 participants were treated.
Participant milestones
| Measure |
Rituximab-Lenalidomide
Rituximab, 375 mg/m\^2 on days
1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; and 8 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles. Six cycles of lenalidomide 20 mg daily on days 2-22 every 28 days.
|
Investigator Choice
Rituximab-CHOP: with six cycles of R-CHOP in 21 day cycles followed by two 21 day cycles of 375 mg/m\^2 rituximab and 7 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles, OR Rituximab-CVP: with eight cycles of R-CVP in 21 day cycles; and 7 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles, OR Rituximab-Bendamustine: with rituximab 375 mg/m\^2 (day 1) plus bendamustine 90 mg/m\^2 (days 1 + 2) every 28 days for six cycles; and 8 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles.
|
|---|---|---|
|
Pre-treatment
STARTED
|
513
|
517
|
|
Pre-treatment
COMPLETED
|
507
|
503
|
|
Pre-treatment
NOT COMPLETED
|
6
|
14
|
|
Treatment
STARTED
|
507
|
503
|
|
Treatment
COMPLETED
|
350
|
357
|
|
Treatment
NOT COMPLETED
|
157
|
146
|
Reasons for withdrawal
| Measure |
Rituximab-Lenalidomide
Rituximab, 375 mg/m\^2 on days
1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; and 8 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles. Six cycles of lenalidomide 20 mg daily on days 2-22 every 28 days.
|
Investigator Choice
Rituximab-CHOP: with six cycles of R-CHOP in 21 day cycles followed by two 21 day cycles of 375 mg/m\^2 rituximab and 7 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles, OR Rituximab-CVP: with eight cycles of R-CVP in 21 day cycles; and 7 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles, OR Rituximab-Bendamustine: with rituximab 375 mg/m\^2 (day 1) plus bendamustine 90 mg/m\^2 (days 1 + 2) every 28 days for six cycles; and 8 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles.
|
|---|---|---|
|
Treatment
Progression
|
64
|
71
|
|
Treatment
Toxicity
|
44
|
16
|
|
Treatment
Death
|
0
|
1
|
|
Treatment
Withdrawal by Subject
|
3
|
14
|
|
Treatment
Major protocol violation
|
1
|
6
|
|
Treatment
Other reasons
|
10
|
22
|
|
Treatment
Concurrent illness
|
12
|
9
|
|
Treatment
Insufficient response
|
15
|
3
|
|
Treatment
Voluntary treatment discontinuation
|
8
|
4
|
Baseline Characteristics
Race and Ethnicity were not collected from any participant.
Baseline characteristics by cohort
| Measure |
Rituximab-Lenalidomide
n=513 Participants
Rituximab, 375 mg/m\^2 on days
1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; and 8 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles. Six cycles of lenalidomide 20 mg daily on days 2-22 every 28 days.
|
Investigator Choice
n=517 Participants
Rituximab-CHOP: with six cycles of R-CHOP in 21 day cycles followed by two 21 day cycles of 375 mg/m\^2 rituximab and 7 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles, OR Rituximab-CVP: with eight cycles of R-CVP in 21 day cycles; and 7 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles, OR Rituximab-Bendamustine: with rituximab 375 mg/m\^2 (day 1) plus bendamustine 90 mg/m\^2 (days 1 + 2) every 28 days for six cycles; and 8 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles.
|
Total
n=1030 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
58.5 Years
STANDARD_DEVIATION 11.23 • n=513 Participants
|
58.3 Years
STANDARD_DEVIATION 11.38 • n=517 Participants
|
58.4 Years
STANDARD_DEVIATION 11.30 • n=1030 Participants
|
|
Sex: Female, Male
Female
|
262 Participants
n=513 Participants
|
266 Participants
n=517 Participants
|
528 Participants
n=1030 Participants
|
|
Sex: Female, Male
Male
|
251 Participants
n=513 Participants
|
251 Participants
n=517 Participants
|
502 Participants
n=1030 Participants
|
|
Race and Ethnicity Not Collected
|
—
|
—
|
0 Participants
Race and Ethnicity were not collected from any participant.
|
PRIMARY outcome
Timeframe: At 120 weeksPopulation: All randomized participants
The Complete Response Rate (CR/CRu) is the percentage of participants who achieve complete response (CR/CRu) at 120 weeks as assessed per Independent Central Review. * Complete Response (CR): Disappearance of all evidence of disease. * Complete Response Unconfirmed (CRu): Disappearance of all disease with the exception of residual lymph nodes that are 1.5 cm or less in greatest transverse diameter and/or indeterminate bone marrow findings.
Outcome measures
| Measure |
Rituximab-Lenalidomide
n=513 Participants
Rituximab, 375 mg/m\^2 on days
1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; and 8 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles. Six cycles of lenalidomide 20 mg daily on days 2-22 every 28 days.
|
Investigator Choice
n=517 Participants
Rituximab-CHOP: with six cycles of R-CHOP in 21 day cycles followed by two 21 day cycles of 375 mg/m\^2 rituximab and 7 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles, OR Rituximab-CVP: with eight cycles of R-CVP in 21 day cycles; and 7 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles, OR Rituximab-Bendamustine: with rituximab 375 mg/m\^2 (day 1) plus bendamustine 90 mg/m\^2 (days 1 + 2) every 28 days for six cycles; and 8 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles.
|
|---|---|---|
|
Complete Response Rate (CR/CRu) at 120 Weeks by Independent Central Review
|
48.1 Percent of participants
Interval 43.7 to 52.6
|
53.0 Percent of participants
Interval 48.6 to 57.4
|
PRIMARY outcome
Timeframe: From randomization into the study to the first observation of documented disease progression or death due to any cause (up to approximately 140 months).Population: All randomized participants
Progression-free survival (PFS) is defined as the time from randomization into the study to the first observation of documented disease progression or death due to any cause. Progressive Disease (PD) is characterized by any of the following: * An increase of at least 50% in the sum of the products of the greatest diameters (SPD) of any previously identified abnormal lymph node(s) or other disease sites. * The appearance of any new lesion during or after treatment. * An increase of at least 50% in the longest diameter of a previously identified node that was 1 cm or more in its short axis. * An increase of at least 50% in the size of other lesions (e.g., splenomegaly, hepatomegaly). Based on Kaplan-Meier estimates.
Outcome measures
| Measure |
Rituximab-Lenalidomide
n=513 Participants
Rituximab, 375 mg/m\^2 on days
1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; and 8 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles. Six cycles of lenalidomide 20 mg daily on days 2-22 every 28 days.
|
Investigator Choice
n=517 Participants
Rituximab-CHOP: with six cycles of R-CHOP in 21 day cycles followed by two 21 day cycles of 375 mg/m\^2 rituximab and 7 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles, OR Rituximab-CVP: with eight cycles of R-CVP in 21 day cycles; and 7 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles, OR Rituximab-Bendamustine: with rituximab 375 mg/m\^2 (day 1) plus bendamustine 90 mg/m\^2 (days 1 + 2) every 28 days for six cycles; and 8 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles.
|
|---|---|---|
|
Progression-free Survival (PFS)
|
120.2 Months
Interval 104.9 to 126.3
|
123.8 Months
Interval 107.4 to
Insufficient number of participants with events
|
SECONDARY outcome
Timeframe: At 120 weeksPopulation: All randomized participants
The Complete Response Rate (CR) is the percentage of participants who achieve confirmed complete response (CR) at 120 weeks as assessed per Independent Central Review. \- Complete Response (CR): Disappearance of all evidence of disease.
Outcome measures
| Measure |
Rituximab-Lenalidomide
n=513 Participants
Rituximab, 375 mg/m\^2 on days
1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; and 8 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles. Six cycles of lenalidomide 20 mg daily on days 2-22 every 28 days.
|
Investigator Choice
n=517 Participants
Rituximab-CHOP: with six cycles of R-CHOP in 21 day cycles followed by two 21 day cycles of 375 mg/m\^2 rituximab and 7 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles, OR Rituximab-CVP: with eight cycles of R-CVP in 21 day cycles; and 7 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles, OR Rituximab-Bendamustine: with rituximab 375 mg/m\^2 (day 1) plus bendamustine 90 mg/m\^2 (days 1 + 2) every 28 days for six cycles; and 8 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles.
|
|---|---|---|
|
Complete Response Rate (CR) at 120 Weeks Per Independent Central Review
|
27.7 Percent of participants
Interval 23.8 to 31.8
|
32.7 Percent of participants
Interval 28.7 to 36.9
|
SECONDARY outcome
Timeframe: From randomization to the date of first documented progression, relapse, and initiation of a new anti-lymphoma treatment or death by any cause (up to approximately 140 months).Population: All randomized participants
Event Free Survival (EFS) is defined as the time a participant remains free from certain negative events (disease progression, relapse, initiation of a new anti-lymphoma treatment, or death) between the date of randomization to the date of first documented progression, relapse, and initiation of a new anti-lymphoma treatment or death by any cause. Responding participants and those lost to follow up were censored at their last tumor assessment date. Progressive Disease (PD) is characterized by any of the following: * An increase of at least 50% in the sum of the products of the greatest diameters (SPD) of any previously identified abnormal lymph node(s) or other disease sites. * The appearance of any new lesion during or after treatment. * An increase of at least 50% in the longest diameter of a previously identified node that was 1 cm or more in its short axis. * An increase of at least 50% in the size of other lesions (e.g., splenomegaly, hepatomegaly). Based on Kaplan-Meier estimates.
Outcome measures
| Measure |
Rituximab-Lenalidomide
n=513 Participants
Rituximab, 375 mg/m\^2 on days
1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; and 8 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles. Six cycles of lenalidomide 20 mg daily on days 2-22 every 28 days.
|
Investigator Choice
n=517 Participants
Rituximab-CHOP: with six cycles of R-CHOP in 21 day cycles followed by two 21 day cycles of 375 mg/m\^2 rituximab and 7 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles, OR Rituximab-CVP: with eight cycles of R-CVP in 21 day cycles; and 7 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles, OR Rituximab-Bendamustine: with rituximab 375 mg/m\^2 (day 1) plus bendamustine 90 mg/m\^2 (days 1 + 2) every 28 days for six cycles; and 8 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles.
|
|---|---|---|
|
Event-free Survival (EFS)
|
130.6 Months
Interval 121.9 to
Insufficient number of participants with events
|
132.3 Months
Interval 115.7 to
Insufficient number of participants with events
|
SECONDARY outcome
Timeframe: From randomization to the date of death by any cause (up to approximately 144 months).Population: All randomized participants
Overall survival (OS) is defined as the median length of time a participant stays alive from randomization. Participants who died, regardless of the cause of death, were considered to have had an event. Participants who withdrew consent for the study were considered censored at the time of withdrawal. Participants who completed the study and were still alive at the time of the clinical data cut-off date were censored. All participants who were lost to follow-up prior to the clinical data cut-off date were also considered censored at the time of last contact. Based on Kaplan-Meier estimates.
Outcome measures
| Measure |
Rituximab-Lenalidomide
n=513 Participants
Rituximab, 375 mg/m\^2 on days
1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; and 8 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles. Six cycles of lenalidomide 20 mg daily on days 2-22 every 28 days.
|
Investigator Choice
n=517 Participants
Rituximab-CHOP: with six cycles of R-CHOP in 21 day cycles followed by two 21 day cycles of 375 mg/m\^2 rituximab and 7 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles, OR Rituximab-CVP: with eight cycles of R-CVP in 21 day cycles; and 7 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles, OR Rituximab-Bendamustine: with rituximab 375 mg/m\^2 (day 1) plus bendamustine 90 mg/m\^2 (days 1 + 2) every 28 days for six cycles; and 8 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles.
|
|---|---|---|
|
Overall Survival (OS)
|
NA Months
Insufficient number of participants with events
|
NA Months
Insufficient number of participants with events
|
SECONDARY outcome
Timeframe: From the date of randomization to the date of the first documented administration of any new anti-lymphoma treatment (up to approximately 140 months).Population: All randomized participants
Time to Next Lymphoma Treatment (TTNLT) was measured from the date of randomization to the date of the first documented administration of any new anti-lymphoma treatment (such as chemotherapy, radiotherapy, radio-immunotherapy, or immunotherapy). Participants who continued to respond to treatment or who were lost to follow-up were considered censored on their last visit date. Participants who died (due to any cause) before receiving a new anti-lymphoma treatment were included in the statistical analysis, with death being counted as an event. Based on Kaplan-Meier estimates.
Outcome measures
| Measure |
Rituximab-Lenalidomide
n=513 Participants
Rituximab, 375 mg/m\^2 on days
1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; and 8 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles. Six cycles of lenalidomide 20 mg daily on days 2-22 every 28 days.
|
Investigator Choice
n=517 Participants
Rituximab-CHOP: with six cycles of R-CHOP in 21 day cycles followed by two 21 day cycles of 375 mg/m\^2 rituximab and 7 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles, OR Rituximab-CVP: with eight cycles of R-CVP in 21 day cycles; and 7 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles, OR Rituximab-Bendamustine: with rituximab 375 mg/m\^2 (day 1) plus bendamustine 90 mg/m\^2 (days 1 + 2) every 28 days for six cycles; and 8 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles.
|
|---|---|---|
|
Time to Next Anti-Lymphoma Treatment (TTNLT)
|
NA Months
Insufficient number of participants with events
|
NA Months
Insufficient number of participants with events
|
Adverse Events
Rituximab-Lenalidomide
Serious events: 181 serious events
Other events: 496 other events
Deaths: 88 deaths
Investigator Choice Rituximab-CHOP
Serious events: 109 serious events
Other events: 351 other events
Deaths: 71 deaths
Investigator Choice Rituximab-CVP
Serious events: 7 serious events
Other events: 26 other events
Deaths: 7 deaths
Investigator Choice Rituximab-Bendamustine
Serious events: 32 serious events
Other events: 108 other events
Deaths: 12 deaths
Serious adverse events
| Measure |
Rituximab-Lenalidomide
n=507 participants at risk
Rituximab, 375 mg/m\^2 on days
1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; and 8 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles. Six cycles of lenalidomide 20 mg daily on days 2-22 every 28 days.
|
Investigator Choice Rituximab-CHOP
n=365 participants at risk
Six cycles of R-CHOP in 21 day cycles followed by two 21 day cycles of 375 mg/m\^2 rituximab and 7 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles.
|
Investigator Choice Rituximab-CVP
n=26 participants at risk
Eight cycles of R-CVP in 21 day cycles; and 7 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles.
|
Investigator Choice Rituximab-Bendamustine
n=112 participants at risk
Rituximab 375 mg/m\^2 (day 1) plus bendamustine 90 mg/m\^2 (days 1 + 2) every 28 days for six cycles; and 8 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles.
|
|---|---|---|---|---|
|
Blood and lymphatic system disorders
AGRANULOCYTOSIS
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Blood and lymphatic system disorders
EOSINOPHILIA
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Blood and lymphatic system disorders
FEBRILE BONE MARROW APLASIA
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.82%
3/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Blood and lymphatic system disorders
FEBRILE NEUTROPENIA
|
1.8%
9/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
4.7%
17/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.8%
1/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
5.4%
6/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Blood and lymphatic system disorders
IRON DEFICIENCY ANAEMIA
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Blood and lymphatic system disorders
NEUTROPENIA
|
0.59%
3/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.82%
3/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Blood and lymphatic system disorders
PANCYTOPENIA
|
0.39%
2/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Blood and lymphatic system disorders
THROMBOCYTOPENIA
|
0.59%
3/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Cardiac disorders
ACUTE CORONARY SYNDROME
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Cardiac disorders
ACUTE MYOCARDIAL INFARCTION
|
0.39%
2/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Cardiac disorders
ANGINA PECTORIS
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.89%
1/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Cardiac disorders
AORTIC VALVE INCOMPETENCE
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Cardiac disorders
ARRHYTHMIA
|
0.39%
2/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Cardiac disorders
ATRIAL FIBRILLATION
|
0.59%
3/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Cardiac disorders
ATRIAL FLUTTER
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Cardiac disorders
ATRIOVENTRICULAR BLOCK COMPLETE
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Cardiac disorders
BRADYCARDIA
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Cardiac disorders
CARDIAC ARREST
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Cardiac disorders
CARDIAC FAILURE
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.8%
1/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Cardiac disorders
CARDIOMYOPATHY
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Cardiac disorders
CARDIORENAL SYNDROME
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Cardiac disorders
CARDIOTOXICITY
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Cardiac disorders
CORONARY ARTERY STENOSIS
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Cardiac disorders
MYOCARDIAL INFARCTION
|
0.39%
2/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.89%
1/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Cardiac disorders
MYOCARDIAL ISCHAEMIA
|
0.39%
2/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Cardiac disorders
PALPITATIONS
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Cardiac disorders
PERICARDIAL EFFUSION
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Cardiac disorders
SINUS NODE DYSFUNCTION
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Congenital, familial and genetic disorders
BRUGADA SYNDROME
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Congenital, familial and genetic disorders
GASTROINTESTINAL MALFORMATION
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Ear and labyrinth disorders
VERTIGO
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.89%
1/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Endocrine disorders
HYPERTHYROIDISM
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Eye disorders
CATARACT
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Eye disorders
PAPILLOEDEMA
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Eye disorders
RETINAL DETACHMENT
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Gastrointestinal disorders
ABDOMINAL PAIN
|
0.39%
2/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.82%
3/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Gastrointestinal disorders
ABDOMINAL PAIN UPPER
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Gastrointestinal disorders
ASCITES
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Gastrointestinal disorders
COLITIS
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.55%
2/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Gastrointestinal disorders
COLITIS ISCHAEMIC
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Gastrointestinal disorders
CONSTIPATION
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.82%
3/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Gastrointestinal disorders
DIARRHOEA
|
0.79%
4/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.82%
3/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Gastrointestinal disorders
DIVERTICULUM INTESTINAL
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Gastrointestinal disorders
ENTEROCOLITIS
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Gastrointestinal disorders
FAECALOMA
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Gastrointestinal disorders
GASTRITIS
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.8%
1/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Gastrointestinal disorders
GASTROINTESTINAL HAEMORRHAGE
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Gastrointestinal disorders
GASTROINTESTINAL PAIN
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Gastrointestinal disorders
HERNIAL EVENTRATION
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Gastrointestinal disorders
INGUINAL HERNIA
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.55%
2/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Gastrointestinal disorders
INTESTINAL OBSTRUCTION
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.8%
1/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Gastrointestinal disorders
NAUSEA
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.82%
3/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.89%
1/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Gastrointestinal disorders
OESOPHAGITIS
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Gastrointestinal disorders
PANCREATITIS
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Gastrointestinal disorders
PANCREATITIS ACUTE
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Gastrointestinal disorders
POOR DENTAL CONDITION
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Gastrointestinal disorders
SMALL INTESTINAL OBSTRUCTION
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.89%
1/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Gastrointestinal disorders
SUBILEUS
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.55%
2/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Gastrointestinal disorders
VOMITING
|
0.39%
2/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.55%
2/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.89%
1/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
General disorders
ADVERSE DRUG REACTION
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
General disorders
ASTHENIA
|
0.39%
2/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
General disorders
CARDIAC DEATH
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
General disorders
CHEST PAIN
|
0.39%
2/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.55%
2/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.8%
1/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
General disorders
FACE OEDEMA
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
General disorders
FATIGUE
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.89%
1/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
General disorders
FOREIGN BODY REACTION
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
General disorders
GENERAL PHYSICAL HEALTH DETERIORATION
|
0.79%
4/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
General disorders
HYPERTHERMIA
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
General disorders
INFLUENZA LIKE ILLNESS
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
General disorders
MALAISE
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
General disorders
MUCOSAL INFLAMMATION
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
General disorders
OEDEMA PERIPHERAL
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.8%
1/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
General disorders
PYREXIA
|
2.6%
13/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.55%
2/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.89%
1/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
General disorders
STRANGULATED HERNIA
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Hepatobiliary disorders
BILIARY DILATATION
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Hepatobiliary disorders
BILIARY OBSTRUCTION
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Hepatobiliary disorders
CHOLANGITIS ACUTE
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Hepatobiliary disorders
CHOLECYSTITIS
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Hepatobiliary disorders
CHOLECYSTITIS ACUTE
|
0.39%
2/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Hepatobiliary disorders
CHOLELITHIASIS
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Hepatobiliary disorders
HEPATITIS
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Hepatobiliary disorders
PORTAL VEIN THROMBOSIS
|
0.39%
2/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Immune system disorders
ANAPHYLACTIC REACTION
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Immune system disorders
ANAPHYLACTIC SHOCK
|
0.39%
2/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Immune system disorders
ANAPHYLACTOID REACTION
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Immune system disorders
DRUG HYPERSENSITIVITY
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.89%
1/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Immune system disorders
HYPERSENSITIVITY
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
APPENDICITIS
|
0.39%
2/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
BACTERIAL SEPSIS
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
BACTERIURIA
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
BRONCHIOLITIS
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
BRONCHITIS
|
0.39%
2/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
CAMPYLOBACTER SEPSIS
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
CELLULITIS
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.89%
1/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
CLOSTRIDIUM DIFFICILE INFECTION
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
DEVICE RELATED SEPSIS
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
ENTEROBACTER SEPSIS
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
ERYSIPELAS
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
ESCHERICHIA SEPSIS
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
ESCHERICHIA URINARY TRACT INFECTION
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
FUSOBACTERIUM INFECTION
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
GANGRENE
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
GASTROENTERITIS
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
GASTROENTERITIS VIRAL
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.89%
1/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
GENITAL HERPES SIMPLEX
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
H1N1 INFLUENZA
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
HEPATITIS E
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
HERPES OPHTHALMIC
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
HERPES ZOSTER
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
HUMAN EHRLICHIOSIS
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.89%
1/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
INFECTION
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.55%
2/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
INFLUENZA
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.55%
2/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.8%
1/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
LARGE INTESTINE INFECTION
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.8%
1/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
MENINGITIS
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.89%
1/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
OESOPHAGEAL CANDIDIASIS
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
PARONYCHIA
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
PERITONITIS
|
0.39%
2/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
PHARYNGITIS
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
PILONIDAL DISEASE
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
PNEUMOCYSTIS JIROVECII PNEUMONIA
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.55%
2/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
PNEUMONIA
|
2.2%
11/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
1.6%
6/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
2.7%
3/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
PNEUMONIA HAEMOPHILUS
|
0.39%
2/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
PNEUMONIA PNEUMOCOCCAL
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
PNEUMONIA STAPHYLOCOCCAL
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
PNEUMONIA STREPTOCOCCAL
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
PNEUMONIA VIRAL
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
PSEUDOMONAL SEPSIS
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
PSEUDOMONAS INFECTION
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
PYELONEPHRITIS
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
PYELONEPHRITIS ACUTE
|
0.39%
2/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
RESPIRATORY TRACT INFECTION
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
SEPSIS
|
0.39%
2/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
SEPTIC SHOCK
|
0.39%
2/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.55%
2/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
SINUSITIS
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.8%
1/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
SOFT TISSUE INFECTION
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.8%
1/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
TONSILLITIS
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
TOOTH ABSCESS
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
UPPER RESPIRATORY TRACT INFECTION
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
URINARY TRACT INFECTION
|
0.99%
5/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
URINARY TRACT INFECTION ENTEROCOCCAL
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
UROSEPSIS
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.8%
1/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
VIRAL INFECTION
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
WOUND INFECTION BACTERIAL
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
WOUND INFECTION STAPHYLOCOCCAL
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Injury, poisoning and procedural complications
ACCIDENTAL OVERDOSE
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Injury, poisoning and procedural complications
AORTIC INJURY
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.89%
1/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Injury, poisoning and procedural complications
CHEST INJURY
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Injury, poisoning and procedural complications
FALL
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.89%
1/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Injury, poisoning and procedural complications
FEMUR FRACTURE
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.89%
1/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Injury, poisoning and procedural complications
HAND FRACTURE
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Injury, poisoning and procedural complications
HIP FRACTURE
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Injury, poisoning and procedural complications
HUMERUS FRACTURE
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Injury, poisoning and procedural complications
INCISIONAL HERNIA
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Injury, poisoning and procedural complications
INFUSION RELATED REACTION
|
1.8%
9/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.89%
1/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Injury, poisoning and procedural complications
LIGAMENT RUPTURE
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Injury, poisoning and procedural complications
MULTIPLE INJURIES
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Injury, poisoning and procedural complications
POSTOPERATIVE WOUND COMPLICATION
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Injury, poisoning and procedural complications
RADIUS FRACTURE
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Injury, poisoning and procedural complications
SPINAL COLUMN INJURY
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Injury, poisoning and procedural complications
SPINAL COMPRESSION FRACTURE
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Injury, poisoning and procedural complications
SPINAL FRACTURE
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Injury, poisoning and procedural complications
ULNA FRACTURE
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Investigations
ELECTROCARDIOGRAM T WAVE INVERSION
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.89%
1/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Investigations
FIBRIN D DIMER INCREASED
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Investigations
TROPONIN INCREASED
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Investigations
TROPONIN T INCREASED
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Investigations
URINE OUTPUT DECREASED
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.89%
1/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Investigations
WEIGHT DECREASED
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Metabolism and nutrition disorders
DECREASED APPETITE
|
0.39%
2/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Metabolism and nutrition disorders
DEHYDRATION
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Metabolism and nutrition disorders
DIABETES MELLITUS
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Metabolism and nutrition disorders
DIABETES MELLITUS INADEQUATE CONTROL
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Metabolism and nutrition disorders
DIABETIC KETOACIDOSIS
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.89%
1/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Metabolism and nutrition disorders
HYPERCALCAEMIA
|
0.39%
2/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Metabolism and nutrition disorders
HYPERGLYCAEMIA
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Metabolism and nutrition disorders
HYPERKALAEMIA
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Metabolism and nutrition disorders
HYPOALBUMINAEMIA
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Metabolism and nutrition disorders
HYPOKALAEMIA
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Metabolism and nutrition disorders
HYPONATRAEMIA
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Metabolism and nutrition disorders
MALNUTRITION
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Metabolism and nutrition disorders
TUMOUR LYSIS SYNDROME
|
0.59%
3/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.89%
1/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Musculoskeletal and connective tissue disorders
ARTHRALGIA
|
0.39%
2/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Musculoskeletal and connective tissue disorders
BACK PAIN
|
0.59%
3/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Musculoskeletal and connective tissue disorders
BONE PAIN
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.55%
2/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Musculoskeletal and connective tissue disorders
CHONDROCALCINOSIS
|
0.39%
2/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Musculoskeletal and connective tissue disorders
FLANK PAIN
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.89%
1/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Musculoskeletal and connective tissue disorders
INTERVERTEBRAL DISC PROTRUSION
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Musculoskeletal and connective tissue disorders
NECK PAIN
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Renal and urinary disorders
RENAL FAILURE
|
0.99%
5/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Musculoskeletal and connective tissue disorders
OSTEOARTHRITIS
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Musculoskeletal and connective tissue disorders
OSTEONECROSIS OF JAW
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Musculoskeletal and connective tissue disorders
SOFT TISSUE NECROSIS
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Musculoskeletal and connective tissue disorders
SPINAL STENOSIS
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Musculoskeletal and connective tissue disorders
SPONDYLITIS
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
ACUTE LYMPHOCYTIC LEUKAEMIA
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
ADENOCARCINOMA OF COLON
|
0.39%
2/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BASAL CELL CARCINOMA
|
0.79%
4/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
1.4%
5/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.6%
4/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BENIGN NEOPLASM OF EPIDIDYMIS
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BENIGN RENAL NEOPLASM
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BOWEN'S DISEASE
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BREAST CANCER
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
CLEAR CELL RENAL CELL CARCINOMA
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
COLON CANCER
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
COLORECTAL ADENOMA
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
ENDOMETRIAL CANCER
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
GALLBLADDER ADENOCARCINOMA
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
INVASIVE DUCTAL BREAST CARCINOMA
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.89%
1/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
KERATOACANTHOMA
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LARYNGEAL SQUAMOUS CELL CARCINOMA
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LUNG ADENOCARCINOMA
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LUNG NEOPLASM MALIGNANT
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LUNG SQUAMOUS CELL CARCINOMA STAGE III
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LYMPHOPROLIFERATIVE DISORDER
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MALIGNANT MELANOMA
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MENINGIOMA
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MENINGIOMA BENIGN
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
NON-SMALL CELL LUNG CANCER
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.89%
1/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PAPILLARY THYROID CANCER
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.89%
1/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
RECTAL ADENOCARCINOMA
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
RENAL CANCER
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.89%
1/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SKIN CANCER
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SMALL CELL LUNG CANCER METASTATIC
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SQUAMOUS CELL CARCINOMA
|
0.39%
2/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SQUAMOUS CELL CARCINOMA OF LUNG
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.89%
1/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SQUAMOUS CELL CARCINOMA OF SKIN
|
0.79%
4/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.8%
1/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
5.4%
6/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SQUAMOUS CELL CARCINOMA OF THE CERVIX
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SQUAMOUS CELL CARCINOMA OF THE TONGUE
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
TUMOUR FLARE
|
0.99%
5/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
UTERINE LEIOMYOMA
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Nervous system disorders
CARPAL TUNNEL SYNDROME
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Nervous system disorders
CEREBRAL INFARCTION
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Nervous system disorders
CEREBROVASCULAR ACCIDENT
|
0.59%
3/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Nervous system disorders
HEADACHE
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.55%
2/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Nervous system disorders
ISCHAEMIC STROKE
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Nervous system disorders
MIGRAINE WITH AURA
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Nervous system disorders
OPTIC NEURITIS
|
0.39%
2/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Nervous system disorders
SCIATICA
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Nervous system disorders
SEIZURE
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Nervous system disorders
SPEECH DISORDER
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Nervous system disorders
SYNCOPE
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.8%
1/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.89%
1/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Nervous system disorders
TRANSIENT ISCHAEMIC ATTACK
|
0.39%
2/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.8%
1/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Product Issues
DEVICE BREAKAGE
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Psychiatric disorders
BIPOLAR DISORDER
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Psychiatric disorders
CONVERSION DISORDER
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Psychiatric disorders
DEPRESSION
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Psychiatric disorders
MANIA
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.89%
1/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Renal and urinary disorders
ACUTE KIDNEY INJURY
|
0.59%
3/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.55%
2/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.8%
1/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Renal and urinary disorders
CALCULUS URINARY
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Renal and urinary disorders
CYSTITIS HAEMORRHAGIC
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Renal and urinary disorders
HAEMATURIA
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Renal and urinary disorders
HYDRONEPHROSIS
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Renal and urinary disorders
NEPHROLITHIASIS
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Renal and urinary disorders
POLLAKIURIA
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Renal and urinary disorders
RENAL TUBULAR NECROSIS
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Renal and urinary disorders
URINARY RETENTION
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Reproductive system and breast disorders
CYSTOCELE
|
0.39%
2/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Reproductive system and breast disorders
PENILE ADHESION
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Reproductive system and breast disorders
PROSTATITIS
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.8%
1/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Respiratory, thoracic and mediastinal disorders
ACUTE PULMONARY OEDEMA
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Respiratory, thoracic and mediastinal disorders
ASTHMA
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Respiratory, thoracic and mediastinal disorders
BRONCHOPNEUMOPATHY
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Respiratory, thoracic and mediastinal disorders
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
|
0.39%
2/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Respiratory, thoracic and mediastinal disorders
COUGH
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.89%
1/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Respiratory, thoracic and mediastinal disorders
DYSPNOEA
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.89%
1/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Respiratory, thoracic and mediastinal disorders
INTERSTITIAL LUNG DISEASE
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Respiratory, thoracic and mediastinal disorders
LARYNGEAL OEDEMA
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Respiratory, thoracic and mediastinal disorders
LUNG DISORDER
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.8%
1/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Respiratory, thoracic and mediastinal disorders
PLEURAL EFFUSION
|
1.8%
9/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Respiratory, thoracic and mediastinal disorders
PLEURITIC PAIN
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.8%
1/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Respiratory, thoracic and mediastinal disorders
PNEUMONITIS
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.55%
2/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.89%
1/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Respiratory, thoracic and mediastinal disorders
PNEUMOTHORAX
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Respiratory, thoracic and mediastinal disorders
PULMONARY EMBOLISM
|
0.99%
5/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.55%
2/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.89%
1/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Respiratory, thoracic and mediastinal disorders
PULMONARY OEDEMA
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Respiratory, thoracic and mediastinal disorders
RESPIRATORY FAILURE
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.55%
2/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Skin and subcutaneous tissue disorders
CAPILLARITIS
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Skin and subcutaneous tissue disorders
CUTANEOUS VASCULITIS
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Skin and subcutaneous tissue disorders
DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Skin and subcutaneous tissue disorders
ECZEMA
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Skin and subcutaneous tissue disorders
HYPERSENSITIVITY VASCULITIS
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Skin and subcutaneous tissue disorders
NEUTROPHILIC DERMATOSIS
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.8%
1/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Skin and subcutaneous tissue disorders
RASH
|
2.0%
10/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Skin and subcutaneous tissue disorders
RASH MACULO-PAPULAR
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Skin and subcutaneous tissue disorders
RASH PAPULAR
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Skin and subcutaneous tissue disorders
STEVENS-JOHNSON SYNDROME
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Skin and subcutaneous tissue disorders
TOXIC SKIN ERUPTION
|
0.59%
3/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Skin and subcutaneous tissue disorders
URTICARIA
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Skin and subcutaneous tissue disorders
VASCULAR PURPURA
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Surgical and medical procedures
UMBILICAL HERNIA REPAIR
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Vascular disorders
AORTIC ANEURYSM RUPTURE
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Vascular disorders
AORTIC DISSECTION
|
0.39%
2/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Vascular disorders
ARTERIAL THROMBOSIS
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Vascular disorders
ARTERIOVENOUS FISTULA
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Vascular disorders
ARTERITIS
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Vascular disorders
BLEEDING VARICOSE VEIN
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Vascular disorders
DEEP VEIN THROMBOSIS
|
0.39%
2/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.27%
1/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.89%
1/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Vascular disorders
HAEMATOMA
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Vascular disorders
HYPERTENSION
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Vascular disorders
HYPOTENSION
|
0.00%
0/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.89%
1/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Vascular disorders
ORTHOSTATIC HYPOTENSION
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Vascular disorders
PHLEBITIS
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.55%
2/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Vascular disorders
PHLEBITIS SUPERFICIAL
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Vascular disorders
SUPERFICIAL VEIN THROMBOSIS
|
0.39%
2/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Vascular disorders
THROMBOSIS
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Vascular disorders
VASCULITIS
|
0.20%
1/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
Other adverse events
| Measure |
Rituximab-Lenalidomide
n=507 participants at risk
Rituximab, 375 mg/m\^2 on days
1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; and 8 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles. Six cycles of lenalidomide 20 mg daily on days 2-22 every 28 days.
|
Investigator Choice Rituximab-CHOP
n=365 participants at risk
Six cycles of R-CHOP in 21 day cycles followed by two 21 day cycles of 375 mg/m\^2 rituximab and 7 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles.
|
Investigator Choice Rituximab-CVP
n=26 participants at risk
Eight cycles of R-CVP in 21 day cycles; and 7 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles.
|
Investigator Choice Rituximab-Bendamustine
n=112 participants at risk
Rituximab 375 mg/m\^2 (day 1) plus bendamustine 90 mg/m\^2 (days 1 + 2) every 28 days for six cycles; and 8 weeks later responding patients continue with 375 mg/m\^2 rituximab every 8 weeks for 12 cycles.
|
|---|---|---|---|---|
|
Gastrointestinal disorders
ABDOMINAL PAIN
|
15.2%
77/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
7.9%
29/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
7.7%
2/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
10.7%
12/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Gastrointestinal disorders
ABDOMINAL PAIN UPPER
|
7.3%
37/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
12.3%
45/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.8%
1/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
5.4%
6/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Gastrointestinal disorders
CONSTIPATION
|
35.3%
179/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
29.9%
109/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
50.0%
13/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
38.4%
43/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Gastrointestinal disorders
DIARRHOEA
|
36.3%
184/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
13.7%
50/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
23.1%
6/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
33.0%
37/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Gastrointestinal disorders
DYSPEPSIA
|
5.1%
26/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
5.2%
19/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
7.7%
2/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
6.2%
7/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Gastrointestinal disorders
GASTROOESOPHAGEAL REFLUX DISEASE
|
3.6%
18/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
4.1%
15/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
6.2%
7/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Gastrointestinal disorders
NAUSEA
|
19.7%
100/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
35.1%
128/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
26.9%
7/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
64.3%
72/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Gastrointestinal disorders
STOMATITIS
|
3.0%
15/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
7.1%
26/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.8%
1/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
8.0%
9/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Gastrointestinal disorders
VOMITING
|
6.3%
32/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
16.7%
61/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
7.7%
2/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
27.7%
31/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
General disorders
ASTHENIA
|
28.4%
144/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
35.3%
129/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
23.1%
6/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
4.5%
5/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
General disorders
CHILLS
|
3.9%
20/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.55%
2/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.8%
1/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
9.8%
11/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
General disorders
FATIGUE
|
22.9%
116/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
18.4%
67/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
23.1%
6/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
65.2%
73/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
General disorders
INFLUENZA LIKE ILLNESS
|
3.6%
18/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
1.4%
5/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
6.2%
7/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
General disorders
MALAISE
|
2.2%
11/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
2.2%
8/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
5.4%
6/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
General disorders
MUCOSAL INFLAMMATION
|
3.0%
15/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
5.2%
19/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
1.8%
2/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
General disorders
OEDEMA PERIPHERAL
|
13.4%
68/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
8.5%
31/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
15.4%
4/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
10.7%
12/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
General disorders
PAIN
|
1.8%
9/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
2.5%
9/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
7.7%
2/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.6%
4/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
General disorders
PYREXIA
|
17.8%
90/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
11.8%
43/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
15.4%
4/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
20.5%
23/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
BRONCHITIS
|
16.4%
83/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
21.6%
79/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
19.2%
5/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
5.4%
6/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
CONJUNCTIVITIS
|
3.0%
15/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
6.3%
23/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
7.7%
2/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.6%
4/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
FUNGAL INFECTION
|
0.99%
5/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.82%
3/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
7.7%
2/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
2.7%
3/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
GASTROENTERITIS
|
4.7%
24/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
2.7%
10/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
7.7%
2/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.89%
1/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
HERPES ZOSTER
|
1.6%
8/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.8%
14/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
9.8%
11/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
INFLUENZA
|
4.5%
23/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
4.7%
17/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
7.7%
2/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
1.8%
2/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
NASOPHARYNGITIS
|
17.2%
87/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
11.5%
42/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
7.7%
2/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
7.1%
8/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
PHARYNGITIS
|
3.7%
19/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
4.7%
17/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
7.7%
2/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
1.8%
2/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
RHINITIS
|
11.0%
56/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
9.3%
34/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
SINUSITIS
|
8.3%
42/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
5.5%
20/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
7.7%
2/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
9.8%
11/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
UPPER RESPIRATORY TRACT INFECTION
|
9.5%
48/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
6.0%
22/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
19.2%
5/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
25.0%
28/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Infections and infestations
URINARY TRACT INFECTION
|
8.7%
44/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
7.4%
27/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
8.0%
9/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Injury, poisoning and procedural complications
INFUSION RELATED REACTION
|
11.4%
58/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
6.8%
25/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.8%
1/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
25.9%
29/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Investigations
LYMPHOCYTE COUNT DECREASED
|
0.79%
4/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
1.6%
6/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
7.7%
2/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
1.8%
2/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Investigations
WEIGHT DECREASED
|
3.7%
19/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.6%
13/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
7.7%
2/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
8.0%
9/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Investigations
WEIGHT INCREASED
|
1.6%
8/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
1.9%
7/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
7.7%
2/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.89%
1/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Investigations
WHITE BLOOD CELL COUNT DECREASED
|
2.8%
14/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
12.1%
44/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.6%
4/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Metabolism and nutrition disorders
DECREASED APPETITE
|
3.7%
19/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.8%
14/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.8%
1/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
8.9%
10/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Musculoskeletal and connective tissue disorders
ARTHRALGIA
|
15.6%
79/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
14.2%
52/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
15.4%
4/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
21.4%
24/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Musculoskeletal and connective tissue disorders
BACK PAIN
|
14.8%
75/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
13.4%
49/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
19.2%
5/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
9.8%
11/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Musculoskeletal and connective tissue disorders
BONE PAIN
|
4.3%
22/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
10.1%
37/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.8%
1/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
2.7%
3/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Musculoskeletal and connective tissue disorders
MUSCLE SPASMS
|
13.8%
70/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
4.4%
16/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
7.7%
2/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
2.7%
3/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Musculoskeletal and connective tissue disorders
MYALGIA
|
14.4%
73/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
4.4%
16/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
7.7%
2/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
10.7%
12/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Musculoskeletal and connective tissue disorders
PAIN IN EXTREMITY
|
7.7%
39/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
4.1%
15/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
7.7%
2/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
5.4%
6/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Nervous system disorders
DIZZINESS
|
8.9%
45/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
4.7%
17/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
17.9%
20/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Nervous system disorders
DYSGEUSIA
|
4.5%
23/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
6.6%
24/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
4.5%
5/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Nervous system disorders
HEADACHE
|
13.0%
66/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
8.5%
31/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
11.5%
3/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
22.3%
25/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Nervous system disorders
HYPOAESTHESIA
|
1.6%
8/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
2.2%
8/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
5.4%
6/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Nervous system disorders
NEUROPATHY PERIPHERAL
|
6.9%
35/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
19.7%
72/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
7.7%
2/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
5.4%
6/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Nervous system disorders
PARAESTHESIA
|
7.3%
37/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
12.6%
46/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
11.5%
3/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
7.1%
8/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Nervous system disorders
PERIPHERAL SENSORY NEUROPATHY
|
3.6%
18/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
5.8%
21/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
11.5%
3/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
4.5%
5/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Psychiatric disorders
ANXIETY
|
5.3%
27/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
6.6%
24/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
9.8%
11/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Psychiatric disorders
DEPRESSION
|
3.9%
20/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
5.8%
21/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
7.7%
2/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
7.1%
8/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Psychiatric disorders
INSOMNIA
|
6.1%
31/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
9.3%
34/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
11.5%
3/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
18.8%
21/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Respiratory, thoracic and mediastinal disorders
COUGH
|
20.5%
104/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
12.1%
44/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
15.4%
4/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
17.9%
20/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Respiratory, thoracic and mediastinal disorders
DYSPNOEA
|
10.8%
55/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
9.0%
33/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
19.2%
5/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
11.6%
13/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Respiratory, thoracic and mediastinal disorders
DYSPNOEA EXERTIONAL
|
0.79%
4/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.82%
3/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
7.7%
2/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.6%
4/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Respiratory, thoracic and mediastinal disorders
OROPHARYNGEAL PAIN
|
4.9%
25/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.8%
14/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.8%
1/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
8.9%
10/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Respiratory, thoracic and mediastinal disorders
PRODUCTIVE COUGH
|
2.4%
12/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.82%
3/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
7.7%
2/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
2.7%
3/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Respiratory, thoracic and mediastinal disorders
RHINITIS ALLERGIC
|
2.4%
12/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
1.4%
5/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
7.1%
8/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Skin and subcutaneous tissue disorders
ALOPECIA
|
0.99%
5/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
10.7%
39/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
7.7%
2/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.6%
4/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Skin and subcutaneous tissue disorders
DRY SKIN
|
8.7%
44/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.6%
13/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.6%
4/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Skin and subcutaneous tissue disorders
ERYTHEMA
|
7.5%
38/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
2.5%
9/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
7.7%
2/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Skin and subcutaneous tissue disorders
NIGHT SWEATS
|
3.6%
18/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
1.1%
4/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
7.7%
2/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
9.8%
11/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Skin and subcutaneous tissue disorders
PRURITUS
|
17.0%
86/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
6.0%
22/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
11.5%
3/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
8.9%
10/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Skin and subcutaneous tissue disorders
RASH
|
27.8%
141/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
6.0%
22/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.8%
1/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
17.0%
19/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Skin and subcutaneous tissue disorders
RASH MACULO-PAPULAR
|
3.7%
19/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
1.4%
5/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.8%
1/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
5.4%
6/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Vascular disorders
HOT FLUSH
|
3.2%
16/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
1.4%
5/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
5.4%
6/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Vascular disorders
HYPERTENSION
|
4.5%
23/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.6%
13/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
7.7%
2/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
8.0%
9/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Vascular disorders
HYPOTENSION
|
3.2%
16/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
1.4%
5/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
7.7%
2/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.89%
1/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Vascular disorders
PHLEBITIS
|
0.39%
2/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
1.1%
4/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
5.4%
6/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Blood and lymphatic system disorders
ANAEMIA
|
4.9%
25/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
12.1%
44/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
11.5%
3/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
7.1%
8/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Blood and lymphatic system disorders
LEUKOPENIA
|
4.3%
22/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
12.9%
47/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
7.7%
2/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
6.2%
7/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Blood and lymphatic system disorders
LYMPHOPENIA
|
1.4%
7/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
5.2%
19/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.8%
1/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.89%
1/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Blood and lymphatic system disorders
NEUTROPENIA
|
39.3%
199/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
47.1%
172/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
26.9%
7/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
22.3%
25/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Blood and lymphatic system disorders
THROMBOCYTOPENIA
|
3.4%
17/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
3.8%
14/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
9.8%
11/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
|
Cardiac disorders
PALPITATIONS
|
1.4%
7/507 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
2.5%
9/365 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
0.00%
0/26 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
5.4%
6/112 • Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).
The number at Risk for All-Cause Mortality represents all Randomized Participants. Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication. The data for the Investigator Choice chemotherapy arms, previously grouped together, presented separately for each specific chemotherapy treatment that participants received.
|
Additional Information
Bristol-Myers Squibb Study Director
Bristol-Myers Squibb
Phone: Please Email
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.
- Publication restrictions are in place
Restriction type: OTHER